{"disease":{"id":"gne-myopathy","name":"gne myopathy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01784679","title":"GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)","phase":"","overall_status":"COMPLETED","enrollment_count":319,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":false},{"nct_id":"NCT07382128","title":"Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT02736188","title":"Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":143,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":true},{"nct_id":"NCT02377921","title":"Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":true},{"nct_id":"NCT01417533","title":"A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT01830972","title":"An Open Label Phase 2 Extension Study of Higher Dose Sialic Acid-Extended Release (SA-ER) Tablets and Sialic Acid-Immediate Release (SA-IR) Capsules in Patients With Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":true},{"nct_id":"NCT04231266","title":"Multi-Center Study of ManNAc for GNE Myopathy","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":54,"lead_sponsor_name":"Leadiant Biosciences, Inc.","has_results":false},{"nct_id":"NCT03638271","title":"Cardiac Magnetic Resonance in Non Ischemic Cardiomyopathy","phase":"NA","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Reham Sameeh","has_results":false},{"nct_id":"NCT02731690","title":"A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Impairment","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":42,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":true},{"nct_id":"NCT01634750","title":"Phase I Clinical Trial of ManNAc in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT04671472","title":"Efficacy Confirmation Study of NPC-09","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Nobelpharma","has_results":false},{"nct_id":"NCT02346461","title":"An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":true}],"total":12},"guidelines":[],"source":"Drug Landscape verified database"}